CRHR2 and myalgic encephalomeyelitis/chronic fatigue syndrome: The results support CRFR2 involvement in ME/CFS, and identify a treatment paradigm that is Cmax-limited and both AUC- and severity-dependent, leading to sustained symptom improvement.